Mucocutaneous Leishmaniasis: clinical markers in presumptive diagnosis  by Diniz, João Luiz Cioglia Pereira et al.
380
Brazilian Journal of otorhinolaryngology 77 (3) May/June 2011
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Mucocutaneous Leishmaniasis: clinical markers in presumptive 
diagnosis
Abstract
João Luiz Cioglia Pereira Diniz1, Manoel Otávio da Rocha Costa2, Denise Utsch Gonçalves3
1 MD. ENT; MSc student of Infectology and Tropical Medicine.
2 PhD; Professor at the Graduate Studies Program in Health Sciences: Infectology and Tropical Medicine - UFMG.
3 PhD; Professor at the Graduate Studies Program in Health Sciences: Infectology and Tropical Medicine of the Federal University of Minas Gerais - UFMG.
Paper submitted to the BJORL-SGP (Publishing Management System – Brazilian Journal of Otorhinolaryngology) on September 6, 2009; 
and accepted on October 13, 2010. cod. 7308
Mucocutaneous Leishmaniasis (ML) can lead to serious sequela; however, early diagnosis can 
prevent complications.
Aim: To evaluate clinical markers for the early diagnosis of ML.
Materials and Methods: A series study of 21 cases of ML, which were evaluated through clinical 
interview, nasal endoscopy, biopsy and the Montenegro test.
Results: A skin scar and previous diagnosis of cutaneous leishmaniasis (CL) were reported in 
8(38%) patients, and 13(62%) of them denied having had previous CL and had no scar. Nasal/oral 
symptom onset until the ML diagnosis varied from 5 months to 20 years, mean value of 6 years. In the 
Montenegro test, the average size of the papule was 14.5 mm, which did not correlate with disease 
duration (p=0.87). The nose was the most often involved site and the extension of the injured mucosa 
did not correlate with disease duration. The parasite was found in 2 (9.52%) biopsy specimens.
Conclusions: ML diagnosis was late. Finding the parasite in the mucosa, cutaneous scar and/
or previous diagnosis of CL were not clinical markers for ML. ML diagnosis must be based on the 
Montenegro test, chronic nasal and/or oral discharge and histological findings ruling out other 
granulomatous diseases.
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INTRODUCTION
American tegumentary leishmaniasis (ATL) is a 
severe public health problem in Brazil and throughout 
the world, as well. It is endemic in 88 countries and it is 
the second most important disease among those caused 
by protozoa with medical relevance, second only to ma-
laria. Minas Gerais is the eight Brazilian state in number 
of reported cases and the first in Southeastern Brazil in 
terms of number of cases/year. Of the 853 cities in the 
state, 401 have reported ATL transmission. Between 2001 
and 2006, of the 11,007 cases reported in Minas Gerais, 
there were 100 deaths caused by the disease, which has 
a well-established treatment and it must be reported to 
the health authorities1.
ATL is a non-contagious infectious disease, caused 
by different species of protozoa of the Leishmania genus, 
which affects the skin and mucosae. It is primarily a zoo-
notic infection, involving other animals besides humans, 
which can be a secondary infestation2.
Despite being less frequent than the cutaneous 
form, the involvement of the nasal and/or oral mucosae is 
usually more severe, which may leave sequelae and cause 
death3,4. Moreover, the psychosocial stigma arising from 
this disease is something that has not been measured yet 
by health surveillance services, since only those who suffer 
their consequences can feel them, not much for the phy-
sical pain, but rather because of the psychological, social 
and behavioral consequences brought about by this often 
repulsive characteristic of the disease, affecting those who 
develop advanced and mutilating forms of the disease1. 
Development time is the biological factor which determi-
nes the parasite spread and it is one of the main causes 
of the mucosal lesions severity and their consequences3,4.
The ATL incubation period varies substantially. In-
fection in closed populations when the inoculation time 
is identified shows an incubation period of ten to 60 day5. 
The cutaneous form of the disease is the predominant one 
in 95% of the reported cases, followed by the mucosal 
type in 3%-5% of the cases1.
Mucosal leishmaniasis (ML) is a form of tegumentary 
leishmaniasis associated with L. braziliensis, L. panamensis 
and, less frequently, L. amazonensis. In most of the cases, 
the mucosal disease happens after the skin lesions, and the 
diagnosis of the mucosal involvement is established only 
months to years after the clinical cure of the initial skin 
infection site. Some patients may have nasal involvement 
without skin disease6. The goal of the present study is to 
assess the clinical markers which may have an impact on 
the early diagnosis of mucosal leishmaniasis.
MATERIALS AND METHODS
The Reference Ward for Mucosal Leishmaniasis of 
the ENT Annex of our University Hospital has received 
an average of two new cases per month of nasal lesions 
suspected of being mucosal leishmaniasis, coming from 
the municipal health care network. We carried out a cross-
sectional study between April of 2008 and April of 2009, 
when all the patients seen in the ward were assessed by 
a structured interview, ENT exam with nasal endoscopy 
and biopsy of the lesion, when indicated, and followed by 
an initial period of 12 months. As inclusion criterion, we 
used a referral with suspicion of mucosal leishmaniasis  in 
patients who had not been previously treated for cutaneous 
leishmaniasis. Patients with confirmed diagnosis of other 
diseases involving the upper respiratory tract mucosa were 
taken off the study.
The proposed protocol for each patient included 
the following: 1) clinical interview to assess gender, age, 
report of a previous skin lesion, onset of the first symptoms 
on mucosae (in months), mucosal lesion location (nasal 
and/or oropharyngeal); 2) nasal endoscopy specifying the 
sites involved; 3) biopsy of the suspected mucosal lesions; 
4) results from the Montenegro test. Confirmed cases were 
referred to the Reference Center for Infectious and Parasitic 
Diseases of the institution for clinical treatment.
This project was approved by the Ethics in Research 
Committee of the Institution under registration # 292/07. 
The patients were informed about the objectives, metho-
dology and possible risks and benefits of the study, and 
they all signed the informed consent form.
RESULTS
We studied 21 patients with mean age of 59 years, 
standard deviation of 13 years; of these, seven (35%) were 
women and 14 (65%) were men. As far as a past of skin 
lesion is concerned, eight (38%) patients reported prior 
skin lesion and had scars, while 13 (62%) did not remember 
and did not have any scar from previous skin involvement.
Time of nasal and/or oropharyngeal symptoms on-
set until diagnostic definition varied between five months 
and 20 years, with mean duration of six years. Table 1 
shows data from the 21 patients investigated.
The Montenegro test showed a mean papule of 14.5 
mm (SD= 6.8 mm), which was not correlated to disease 
duration (p=0.87, Graph 1).
As to the involvement site, nasal involvement alone 
happened to 10 (47%) cases, simultaneous involvement 
of the nose and oropharynx happened to 10 (47%) and 
the oropharynx alone was involved in one (4.8%) case. 
We did not observe correlation between involvement site 
and the time of symptom onset (p=0.14). We carried out 
a histological assessment of the lesion in 21 patients, and 
the parasite was found in two (9.5%) of the nasal or oral 
mucosae evaluated. Table 1 depicts a summary of the 
data analyzed.
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DISCUSSION
The nasal mucosa is a preferred site for the lesions 
caused by L. braziliensis, although the oral mucosa, pha-
rynx and larynx may also be affected4. Of the 21 patients 
examined, 20 (94%) had nasal lesions alone, or associa-
ted with oropharyngeal lesions. The earliest signs and 
symptoms of mucosal leishmaniasis are nasal obstruction, 
epistaxis - arising from granuloma formation, in a few days 
or months, septum perforation may ensue6.
A past of ATL or a typical skin scar was seen in most 
of the patients assessed. For mucosal leishmaniasis diag-
nosis, clinical history and the typical skin scar have been 
considered important clinical markers to corroborate the 
diagnosis of ML in patients with non-specific granuloma-
tous nasal/oral lesions7. In the present study, a past of skin 
lesion or scan indicating skin leishmaniasis did not prove 
to be a good marker to forecast the diagnosis of mucosal 
leishmaniasis. In this series, 62% of the patients did not 
remember whether or not they had had skin involvement 
and did not have the suggestive scar of a past lesion. This 
is an important piece of information because it reflects 
the limited value of considering the negative history of 
the patient as to prior leishmaniasis or the lack of a scar 
as indicators not to consider the diagnostic hypothesis of 
a mucosal leishmaniasis in a patient with chronic rhinitis 
without a definite diagnosis. Since it is not very common 
Table 1. Patients with recent diagnosis of mucosal leishmaniasis seen in the Otorhinolaryngology clinic of our University Hospital, 
between April of 2008 and April of 2009.
Patient
Gen-
der
Age
(years)
Skin lesion 
Mucosal symptom 
onset (months)
Montenegro test
(mm)
Mucosal lesion 
location
Biopsy (parasite 
present)
01 F 72 Yes 24 10 Nasal/Oropharyn No
02 M 64 No 120 8 Nasal No
03 F 75 No 17 18 Nasal No
04 F 46 Yes 120 22 Nasal No
05 M 69 No - 10 Nasal No
06 M 72 No 24 5 Nasal/Oropharyn No
07 M 56 No 5 13 Nasal/Oropharyn No
08 M 58 No 18 Positivea Nasal/Oropharyn No
09 F 74 No 240 Positivea Nasal/Oropharyn No
10 M 56 No 108 17 Nasal No
11 M 74 Yes 24 Positivea Nasal Yes
12 M 47 Yes 60 Positivea Nasal No
13 M 77 Yes 24 10 Nasal/Oropharyn No
14 M 72 No 24 20 Nasal/Oropharyn No
15 M 45 No 132 25 Nasal/Oropharyn No
16 M 41 Yes 24 Positivea Nasal/Oropharyn Yes
17 M 24 Yes 4 15 Nasal No
18 F 59 No - Positivea Nasal No
19 F 73 No 12 Positivea Oropharynx No
20 M 34 Yes 11 Positivea Nasal/Oropharyn No
21 F 47 No 240 8 Nasal No
aPositive between 10 and 20 mm
Graph 1. Correlation between the Montenegro test and symptom onset 
- Papule diameter in the Montenegro skin test and clinical symptom 
evolution time of the mucosal leishmaniasis of patients seen in the 
Otorhinolaryngology Clinic of the University Hospital between April 
2008 and April of 2009.
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to find the parasite in the skin lesion5,7, confirmed by the 
present study, what we are left with are the immune tests 
to help define the mucosal leishmaniasis.
The early mucosal leishmaniasis diagnosis is the 
main challenge of the Leishmaniasis Tegumentary Ame-
ricana Surveillance Program of the Health Department 
aiming at reducing the deformities caused by the disease2.
The long time passed between symptom onset and 
the etiological diagnosis of the mucosal form of ATL may 
reflect the limitation in the training of most physicians 
concerning a proper approach for mucosal leishmaniasis, 
the general practitioner - often times not trained to pro-
perly approach nasal complaints, or the specialist, who 
frequently only does a nasal biopsy, which, in the case 
of mucosal leishmaniasis, is non-conclusive in most of 
the cases5,7.
Diagnostic delays, which mean time in the present 
study was of six years, could be justified by the fact that 
the patients did not seek medical care. Nonetheless, since 
chronic nasal obstruction is the complaint which has a 
direct impact on the quality of life and the work capacity 
of the individual, it is improbable that such delay has 
been caused by a delay in seeking medical care8. In fact, 
LM patients report having been treated for chronic rhinitis 
during long periods of time, without a definitive etiological 
diagnosis6. In a study carried out in the state of Paraná, 
Silveira et al. reported that the time interval between the 
skin lesion and the nasopharyngeal involvement was of 
up to two years in 30.4% of the patients, and higher than 
ten years in 50.0%9.
The Montenegro skin test is the most broadly used 
and reliable to screen individuals with suspicion of ATL, 
considering the fact that the test has over 90% of sensiti-
vity and specificity, as per shown in different studies4,10-12. 
In endemic areas, the positive Montenegro test can be 
interpreted as previous leishmaniasis, previous injection 
of the  antigen used in the test, exposure to the parasite 
without disease (infection), allergy to the test diluting agent 
or crossed reaction with other diseases (Chagas, sporotri-
chosis, Virchowian leprosy, tuberculosis, chromomycosis, 
and others)2. As it happens to any other screening test, 
result validity will depend on clinical history and disease 
prevalence in the population being studied2. The mean 
papule diameter in the Montenegro test found in the pre-
sent series is in agreement with literature data13, just like 
the lack of correlations between the papule diameter and 
the time of symptom onset.
The search for antibodies by indirect immunofluo-
rescence must not be utilized as the sole criterion for the 
diagnosis of ATL, it may be associated with other diseases 
of the differential diagnosis to the Montenegro test results 
or to other parasitic techniques2. Patients with mucosal 
lesions have higher and more persistent titers of this re-
action, which can be useful to follow up the response to 
treatment in the mucosal form of the disease2,9. Bearing 
in mind that leishmania sp is a protozoa which stimulates 
cell immunity, we can better understand the reason why 
the formation of antibodies is limited, when assessed by 
the immunofluorescence method2,11,14.
The Polymerase Chain Reaction (PCR) is a useful 
tool in the diagnosis of ATL, considering the difficulties in 
isolating the parasites from the mucosal lesions, especially 
when the goal is to identify the species15. The reaction has 
been utilized for research purposes, and it is not very much 
employed in routine diagnostic approaches2.
ATL’s differential diagnoses includes paracoccidio-
idomycosis, epidermoid carcinoma, basal cell carcinoma, 
lymphomas, rhinophyma, rhinosporidiosis, entomophtho-
romycosis, Virchowian leprosy, tertiary syphilis, traumatic 
septal perforation or drug use, allergic rhinitis, sinusitis, 
sarcoidosis, Wegener Granulomatosis, among other rarer 
diseases7,14.
ATL is a disease of mandatory reporting to health 
authorities. All confirmed cases must be reported and 
investigated by health care services by means of the In-
vestigation Form standardized by the Notification Severity 
Information System - Sistema de Informação de Agravos 
de Notificação (SINAN)2. The information system follow 
up and evaluation must be under the responsibility of the 
technical department responsible for the ATL surveillance 
in the three levels of public administration: city, state and 
federal2.
Social and cultural determining factors may impact 
notification. In the study carried out in Acre, and endemic 
area with active public policies to control leishmaniasis, 
it was reported that in the micro region where there was 
a higher incidence of the mucosal form of the disease 
(41.0%), the time interval between symptom onset and me-
dical care varied between 2 and 9 months16. The supposed 
higher occurrence of the mucosal form would probably 
be the result of an active search for suspicious cases and 
an efficient reporting system.
Actions geared towards early diagnosis and proper 
treatment of ATL cases must be the responsibility of mu-
nicipal secretariats of health, with the support of the state 
secretariats and that from the Federal Health Department. 
Patient care may be carried out by means of spontaneous 
demand at the health care centers, by active search of cases 
in transmission areas - when indicated by epidemiological 
surveillance, or by the family health care team; or, still, in 
risky areas where it is difficult for the population to have 
access to health care centers2.
CONCLUSION
In conclusion, the late diagnosis of mucosal leish-
maniasis seems to be associated with educational, social, 
economic and geographic factors. Otorhinolaryngological 
exam associated with the Montenegro test continue to be 
the most important elements for the diagnosis, although 
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usually of presumptive character. We need further studies 
using new techniques aiming at identifying the parasite or 
its components in the mucosal lesions in order to improve 
diagnostic accuracy.
As far as primary health care is concerned, it is 
worth stressing the need to properly train Family Health 
Care Teams to actively search cases in endemic areas, as 
well as to appreciate the complaints of these patients. It 
is probable that a greater availability of the Montenegro 
test and an encouragement concerning continued medical 
education are essential conditions for an early diagnosis 
of ATL.
REFERENCES
 1. Secretaria de Estado da Saúde. Superintendência de Epidemiologia. 
Análise da situação de saúde em Minas Gerais; 2006
 2. Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de 
Vigilância da Leishmaniose Tegumentar Americana. Segunda Edição. 
Brasília - DF; 2007
 3. Passos VMA, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Gontijo 
CMF et al. Leishmaniose tegumentar na Região Metropolitana de Belo 
Horizonte: aspectos clínicos, laboratoriais, terapêuticos e evolutivos 
(1989-1995). Rev Soc Bras Med Trop.2001;34:5-12.
 4. Marsden PD. Mucosal leishmaniasis due to Leishmania (Viannia) 
Braziliensis L(V)b in Três Braços, Bahia - Brazil. Rev Soc Bras Med 
Trop.1994;27(2):93-101.
 5. Carvalho L P, Passos S, Bacellar O, Lessa M, Almeida R P, Magalhães 
A et al. Differencial immune regulation of activated T cells between 
cutaneous and mucosal leishmaniasis as a model for pathogenesis. 
Parasite Immunol.2007;29:251-8.
 6. Lessa MM, Lessa HA, Castro TWN, Oliveira A, Scherifer A, Machado 
P et al. Mucosal leishmaniasis: epidemiological and clinical aspects. 
Braz J Otorhinolaryngol.2007;73(6):843-7.
 7. Boaventura VS, Cafe V, Costa J, Oliveira F, Bafica A, Rosato A et al. 
Concomitant early mucosal and cutaneous leishmaniasis in Brazil. 
Am J Trop Med Hyg.2006;75(2):267-9.
 8. Lambertucci JR, Coulaud R, Silva LCS. Mucosal leishmaniasis. Rev 
Soc Bras Med.2003;36(2):307-8.
 9. Silveira TGV, Arraes SMA, Bertolini DA, Teodoro U, Lonardoni MVC, 
ACBS Roberto. Observações sobre o diagnóstico laboratorial e a 
epidemiologia da leishmaniose tegumentar no Estado do Paraná, sul 
do Brasil. Rev Soc Bras Med.1999;32(4):413-23.
10. Furtado T. Critérios para o diagnóstico da leishmaniose tegumentar 
americana. An Bras Dermatol.1980;55(2):81-6.
11. Follador I, Araujo C, Cardoso MA, Tavares-Neto J, Barral A, Miranda 
JC et al. Surto de leishmaniose tegumentar americana em Canoa, 
Santo Amaro, Bahia, Brasil. Rev Soc Bras Med.1999;32(5):497-503.
12. Stolf HO, Alencar Marques S, Marques MEA, Yoshida ELA, Dillon 
NL. Surto de leishmaniose tegumentar americana em Itaporanga, São 
Paulo (Brasil). Rev Inst Med Trop S Paulo.1993;35(5):437-42.
13. Nogueira MF, Goto H, Sotto MN, Cucé LC. Cytokine profile in Mon-
tenegro skin test of patients with localized cutaneous and mucocu-
taneous leishmaniasis. Rev Inst Med Trop S Paulo.2008;50(6):333-7.
14. Secretaria Municipal de Saúde. Recomendações para o manejo clínico 
da leishmaniose tegumentar e visceral. Belo Horizonte; 2007
15. Bracho CO, Quintana LP, Arenas SM, Parra MR. Polymerase chain 
reaction with two molecular targets in mucosal leishmaniasis diagno-
sis: a validation study. Mem Inst Oswaldo Cruz.2007;102(5):549-54.
16. Silva NS, Viana AB, Cordeiro JA, Cavasini CE. Leishmaniose te-
gumentar americana no estado do Acre, Brasil. Rev Saúde Públi-
ca.1999;33(6):554-9.
